BBB Therapeutics is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with BBB Therapeutics' proprietary G-TechnologyÂŽ for enhanced drug delivery across the blood-brain barrier. BBB Therapeutics currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study.